Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NZV8
UPID:
KCND2_HUMAN
Alternative names:
Voltage-gated potassium channel subunit Kv4.2
Alternative UPACC:
Q9NZV8; O95012; O95021; Q2TBD3; Q9UBY7; Q9UN98; Q9UNH9
Background:
The Potassium voltage-gated channel subfamily D member 2, also known as Kv4.2, is crucial for mediating transmembrane potassium transport in excitable membranes, predominantly in the brain. It plays a pivotal role in regulating neuronal excitability, action potential firing, and contributes to the circadian rhythm of locomotor activity. Kv4.2 forms tetrameric potassium-selective channels, functioning in both homotetrameric and heterotetrameric forms, with its activity modulated by interaction with KCNIP regulatory subunits.
Therapeutic significance:
Understanding the role of Potassium voltage-gated channel subfamily D member 2 could open doors to potential therapeutic strategies.